igeneon AG , a Vienna-based biotech company developing active and passive immunotherapies to treat cancer, was created with Novartis AG 's Phase I epithelial cancer vaccine in mind. The therapeutic candidate—based on an antibody that provokes an immune response to Lewis Y, a sugar expressed on the surface of lung, intestinal, breast, prostate and ovarian cancers—was discovered in the lab of Hans Loibner, PhD, founder and CEO of Igeneon. Loibner had previously spent more than 20 years in various R&D positions at Sandoz, which merged with Ciba-Geigy in 1996 to create Novartis [See Deal].
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?